Teva’s overall performance topped Wall Street estimates for Q1, according to Bloomberg News, which also pointed out that the ...

For an accessible version of this Press Release, please visit Q1 2026 revenues of ~$4.0 billion increased by 2% in U.S.

By Siddhi Mahatole April 29 (Reuters) - Teva Pharmaceutical beat first-quarter profit estimates on Wednesday as growth in its ...

Teva Pharmaceutical Industries TEVA reported first-quarter 2026 adjusted earnings of 53 cents per share, which beat the Zacks ...

Teva Pharmaceutical Industries Ltd (TEVA) reports robust growth in key products and strategic acquisitions, despite facing revenue declines in generics.

Teva's new CEO Richard Francis has his work cut out as the company seeks to recover from a revenue slide. Thanks to declines for several of its offerings, Teva global sales slipped 5% year over year ...

Austedo XR is a vesicular monoamine transporter 2 inhibitor. The Food and Drug Administration (FDA) has approved Austedo ® XR, a new once-daily formulation of deutetrabenazine, for the treatment of ...

Credit: Getty Images. Austedo XR is a vesicular monoamine transporter 2 inhibitor. Austedo ® XR (deutetrabenazine) extended-release tablets are now available for the treatment of adults with tardive ...

Austedo (deutetrabenazine) is a prescription drug used to treat involuntary movements caused by certain conditions. Austedo can interact with alcohol, other drugs, and some supplements. For example, ...

No-moat Teva TEVA reported second-quarter earnings that were slightly ahead of our expectations. Total sales were up 2.4% year over year, driven by strong performance from Teva’s key innovative ...

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), said that the U.S. Food and Drug Administration has approved AUSTEDO XR as a one pill, once-daily ...

Please provide your email address to receive an email when new articles are posted on . Austedo treatment appeared to improve involuntary movements and quality of life among older adults with tardive ...